NCIC CLINICAL TRIALS GROUP – GI DISEASE SITE COMMITTEE

NEUROENDOCRINE
DISEASE ORIENTED GROUP

AGENDA
OPEN SESSION

VENUE: ROSSETTI ROOM, DELTA CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 27TH, 2013

TIME: 10:30 – 11:15

CHAIRS: DR. TIM ASMIS & DR. HAGEN KENNECKE

10:30 WELCOME AND INTRODUCTION
DR. H. KENNECKE AND DR. T. ASMIS

10:30 APPROVED/ACTIVE TRIALS

NEC.2 (CALGB 80701): RANDOMIZED PHASE II STUDY OF EVEROLIMUS ALONE VERSUS EVEROLIMUS PLUS BEVACIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC NEUROENDOCRINE TUMORS
DR. H. KENNECKE

10:45 CONCEPTS IN DEVELOPMENT/TRIAL PROPOSALS

ALLIANCE 021202 (CALGB 81103): PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS
DR. T. ASMIS

ECOG2211: A RANDOMIZED STUDY OF TEMOZOLOMIDE OR TEMOZOLOMIDE-CAPECITABINE IN PATIENTS WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS
DR. T. ASMIS

11:15 CLOSING REMARKS